Drug
Fosigotifator clinical trials
Includes 5 studies of Fosigotifator sodium tromethamine.
- studies test it
- 10
- open now
- 1
- in phase 3
- 1
- first study started
- 2020
Keep track of what changes. Save the fosigotifator studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
10 studies that test it; most in 2024 (4)
| Year | Studies |
|---|---|
| 2020 | 1 |
| 2021 | 1 |
| 2023 | 3 |
| 2024 | 4 |
| 2025 | 1 |
By phase
A phase 1/2 study counts in both.
- Early Phase 1
- 1
- Phase 1
- 7
- Phase 2
- 2
- Phase 3
- 1
- No phase
- 1
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 7 · Other 3
Calico Life Sciences LLC (5) · McGill University Health Centre/Research Institute of the McGill University Health Centre (2) · AbbVie (2) · Merit E. Cudkowicz, MD (1)
Often tested with
Tested in the same studies.
Zilucoplan (1) · AZD3241 (1) · CNM-Au8 (1) · Pridopidine (1) · SLS-005 (1) · Evetifator (1) · NUZ-001 (1)
Studies
Open first, then newest update. How each study uses fosigotifator is read from its arms, and is right about nine times in ten.
Testing it · 10
- An Open-Label Exploratory Study of Fosigotifator in Participants With Vanishing White Matter DiseaseRecruitingPhase 1/2Calico Life Sciences LLCNCT05757141Written as Fosigotifator
- HEALEY ALS Platform Trial - Master ProtocolActive, not recruitingPhase 2/3Merit E. Cudkowicz, MDNCT04297683Written as ABBV-CLS-7262
- Single Patient Investigational Treatment for Cree LeukoencephalopathyActive, not recruitingNot applicableMcGill University Health Centre/Research Institute of the McGill University Health CentreNCT07300397Written as Fosigotifator
- Research Study for Single-Patient Treatment of Cree Leukoencephalopathy/Vanishing White Matter DiseaseActive, not recruitingEarly Phase 1McGill University Health Centre/Research Institute of the McGill University Health CentreNCT07272525Written as Fosigotifator (FGT/ABBV-CLS-7262)
- A Study to Assess Adverse Events of Fosigotifator (ABBV-CLS-7262) in Adults With Major Depressive DisorderTerminatedPhase 1AbbVieNCT06618118Written as Fosigotifator
- A Phase 1 Study to Investigate the Safety and Pharmacokinetics of Fosigotifator in Patients With Amyotrophic Lateral SclerosisTerminatedPhase 1AbbVieNCT04948645Written as Fosigotifator
- Study of [14C] ABBV-CLS-7262 in Healthy Male Volunteers Following Single Oral Dose AdministrationCompletedPhase 1Calico Life Sciences LLCNCT06425003Written as [14C] ABBV-CLS-7262
- A Thorough QT Study of ABBV-CLS-7262 in Healthy SubjectsCompletedPhase 1Calico Life Sciences LLCNCT06310876Written as ABBV-CLS-7262
- A Phase 1 Study Assessing the Effect of Food on the Pharmacokinetics of ABBV- CLS-7262CompletedPhase 1Calico Life Sciences LLCNCT06145607Written as ABBV-CLS-7262
- A Phase 1 Study of ABBV-CLS-7262, Rosuvastatin, and Digoxin in Healthy SubjectsCompletedPhase 1Calico Life Sciences LLCNCT05763459Written as ABBV-CLS-7262
Codes
What other systems call fosigotifator · ClinicalTrials.gg INT014658
- UNII (FDA) 3FQ7XKK8AYFOSIGOTIFATORConfirmed FDA, Wikidata
- Wikidata Q123580749fosigotifatorConfirmed FDA, Wikidata
- NCI Thesaurus C203230FosigotifatorOne source FDA
- DrugBank DB19409One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | 3FQ7XKK8AY | FOSIGOTIFATOR | Confirmed FDA, Wikidata |
| Wikidata | Q123580749 | fosigotifator | Confirmed FDA, Wikidata |
| NCI Thesaurus | C203230 | Fosigotifator | One source FDA |
| DrugBank | DB19409 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.